biological agents volume 100 B A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans

Similar documents
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. VOLUME 93 Carbon Black, Titanium Dioxide, and Talc

Volume 10 Cervix Cancer Screening

Cancer Incidence in Five Continents. Volume VIII

:i iiii ï {:] liii M1!11111[.1i

MONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES

Previous volumes in this series

Photo Book: Identify Signs of Illness

Overheads. Complementary Feeding Counselling a training course. World Health Organization

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

DECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION

GOOD PHARMACOPOEIAL PRACTICES

NATIONAL COORDINATION MECHANISM FOR TOBACCO CONTROL A Model for the African Region

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

State of InequalIty. Reproductive, maternal, newborn and child health. executi ve S ummary

WHO/NMH/TFI/11.3. Warning about the dangers of tobacco. Executive summary. fresh and alive

MONITORING HEALTH INEQUALITY

CUTANEOUS LEISHMANIASIS

GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND

THE SELECTION AND USE OF ESSENTIAL MEDICINES

BEST PRACTICES FOR PLANNING A VACCINATION CAMPAIGN FOR AN ENTIRE POPULATION

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

1.Nicotine - pharmacology 2.Nicotine - standards 3.Tobacco - chemistry 4.Smoking I.Title. ISBN (LC/NLM classification: HD 9130.

Diabetes. Halt the diabetes epidemic

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

Latent tuberculosis infection

Guidelines for scaling-up the 100% condom use programme:

Intercountry meeting of national malaria programme managers from countries of HANMAT and PIAM-Net

BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA

NATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

CLINDAMYCIN PALMITATE

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

Public Health Laboratories for Alert and Response. A WHO Guidance Document

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network

Annie J. Sasco, MD, MPH, MS, DrPH

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

TECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE

IARC A UNIQUE AGENCY. Cancer research for cancer prevention

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,

EMTRICITABINE AND TENOFOVIR TABLETS

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

PRINCIPLES FOR EVALUATING HEALTH RISKS IN CHILDREN ASSOCIATED WITH EXPOSURE TO CHEMICALS

WHO/SDE/WSH/04.08/64s. Trihalomethanes in drinking-water Summary statement

IMPLEMENTATION OF THE REVISED GENERAL

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

preventing suicide Regional strategy on

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

Checklist for assessing the gender responsiveness of sexual and reproductive health policies. Pilot document for adaptation to national contexts

Raising tobacco taxes in Bangladesh in FY : An opportunity for development

Health Risks Assessment A WHO perspective. Dr E. van Deventer

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

LEADING THE HEALTH SECTOR RESPONSE TO HIV/AIDS

REPORT ON THE SPECIAL SESSION ON IDENTIFYING THE PUBLIC HEALTH RESEARCH NEEDS FOR INFLUENZA IN AFRICA 4 JUNE 2010, MARRAKESH, MOROCCO

The WHO International EMF Project: The road ahead

Technical consultation on reducing sugar intake in the Eastern Mediterranean Region

Foodborne disease outbreaks: Guidelines for investigation and control

Public health relevant virological features of Influenza A(H7N9) causing human infection in China

Suicide and Suicide Prevention in Asia

Summary report on the WHO-EM/WRH/104/E

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

Ouagadougou Declaration

UNAIDS Technical Support Division of Labour. Summary & Rationale

CANCER FACT SHEETS: STOMACH CANCER

WHO Regional Office for Europe summary of Middle East respiratory syndrome coronavirus (MERS-CoV) Situation update and overview of available guidance

WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. Volume 5. Sunscreens

WHO Emergency Risk Communication

WEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

CANCER FACT SHEETS: BREAST CANCER

Latent tuberculosis infection

WHO Library Cataloguing in Publication Data. Making your city smoke free: workshop guide

Module 9 Strategic information

Washington County Public Health Achievement Awards

WHO Library Cataloguing-in-Publication Data. World health statistics 2015.

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

Diabetes Action Now. Consultation on a new WHO-IDF programme

The Global Action Plan to increase supply of pandemic influenza vaccines

CANCER FACT SHEETS: LIVER CANCER

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

Scientific Council Fifty-first Session 21/11/2014

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

The carcinogenicity of benzene. The IARC Monograph Vol 120. Kurt Straif, MD MPH PhD. PSA, Stavanger, 25 October 2018

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

SOS Children s Villages International Child Safety and Corruption Prevention

MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA

Eradicating Guinea-Worm Disease

HIV AND INFANT FEEDING FRAMEWORK FOR PRIORITY ACTION

Collective Impact Report

Biochemical Society Centenary: the Last 25 Years

WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION

Management of Tuberculosis Training for Health Facility Staff

hiv/aids Programme meeting report March 2012, Siem Reap, Cambodia Executive Summary

REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition

Transcription:

biological agents volume 100 B A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans

biological agents volume 100 B A review of human carcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24 February-3 March 2009 lyon, france - 2012 iarc monographs on the evaluation of carcinogenic risks to humans

IARC MONOGRAPHS In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. The programme was subsequently expanded to include evaluations of carcinogenic risks associated with exposures to complex mixtures, lifestyle factors and biological and physical agents, as well as those in specific occupations. The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed and on specific exposure situa tions; to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields; and to indicate where additional research efforts are needed. The lists of IARC evaluations are regularly updated and are available on the Internet at http://monographs.iarc.fr/. This programme has been supported since 1982 by Cooperative Agreement U01 CA33193 with the United States National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the Health, Safety and Hygiene at Work Unit of the European Commission Directorate-General for Employment, Social Affairs and Equal Opportunities, and since 1992 by the United States National Institute of Environmental Health Sciences, Department of Health and Human Services. The contents of this volume are solely the responsibility of the Working Group and do not necessarily represent the official views of the U.S. National Cancer Institute, the U.S. National Institute of Environmental Health Sciences, the U.S. Department of Health and Human Services, or the European Commission Directorate-General for Employment, Social Affairs and Equal Opportunities. This volume was made possible, in part, through Cooperative Agreement CR 834012 with the United States Environmental Protection Agency, Office of Research and Development. The contents of this volume do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency. Published by the International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France International Agency for Research on Cancer, 2012 Distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its publications, in part or in full. Requests for permission to reproduce or translate IARC publications whether for sale or for noncommercial distribution should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The IARC Monographs Working Group alone is responsible for the views expressed in this publication. IARC Library Cataloguing in Publication Data A review of human carcinogens. Part B: Biological agents / IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2009: Lyon, France) (IARC monographs on the evaluation of carcinogenic risks to humans ; v. 100B) 1. Biological Products adverse effects 2. Biological Products toxicity 3. Carcinogens 4. Neoplasms etiology I. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans II. Series ISBN 978 92 832 1319 2 (NLM Classification: W1) ISSN 1017-1606 PRINTED IN FRANCE

Lorenzo Tomatis (1929-2007) Founder of the IARC Monographs Programme Lorenzo Tomatis, MD, with other colleagues knowledgeable in primary prevention and environmental carcinogenesis, perceived in the 1960s the growing need to objectively evaluate carcinogenic risks by international groups of experts in chemical carcinogenesis. His vision and determination to provide a reliable source of knowledge and information on environmental and occupational causes of cancer led to his creating the IARC Monographs Programme for evaluating cancer risks to humans from exposures to chemicals. The first meeting, held in Geneva in December 1971, resulted in Volume 1 of the IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man [1972], a series known affectionately since as the orange books. As a champion of chemical carcinogenesis bioassays, Tomatis defined and promoted the applicability and utility of experimental animal findings for identifying carcinogens and for preventing cancers in humans, especially in workers and children, and to eliminate inequalities in judging cancer risks between industrialized and developing countries. Tomatis foresight, guidance, leadership, and staunch belief in primary prevention continued to influence the IARC Monographs as they expanded to encompass personal habits, as well as physical and biological agents. Lorenzo Tomatis had a distinguished career at the Agency, arriving in 1967 and heading the Unit of Chemical Carcinogenesis, before being Director from 1982 to 1993. Volume 100 of the IARC Monographs Series is respectfully dedicated to him. (photo: Roland Dray)